FDA information request to delay Pargluva launch
The FDA has requested additional safety information before it can approve Bristol-Myers Squibb’s potential blockbuster diabetes drug Pargluva (muraglitazar).
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.